Enliven Therapeutics Investor Relations Material
Latest events
Study Update
Enliven Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Enliven Therapeutics Inc
Access all reports
Enliven Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors for cancer treatment. The company aims to address both existing and emerging unmet needs in oncology with a precision approach designed to improve patient survival and overall well-being. Their development pipeline includes advanced candidates such as ELVN-001 and ELVN-002, which are being explored for their potential to offer enhanced selectivity, combinability, and safety in treatment protocols. The company is headquartered in Boulder, Colorado, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ELVN
Country
🇺🇸 United States